Used in pharmaceutical research as a potent and selective inhibitor of cereblon (CRBN), this compound plays a key role in the development of targeted protein degradation therapies. It functions as a molecular glue, enhancing the interaction between cereblon and specific disease-related proteins, leading to their ubiquitination and subsequent degradation by the cell’s proteasome system. This mechanism is being explored for treating cancers, particularly hematological malignancies such as multiple myeloma and myelodysplastic syndromes. Due to its ability to modulate protein-protein interactions, it serves as a valuable tool compound in studies of E3 ubiquitin ligase function and in the design of novel PROTACs (proteolysis-targeting chimeras). Its dihydropyridinone and morpholino moieties contribute to improved solubility and binding specificity, making it suitable for in vitro and in vivo biological assays.